Download PDF
Semin Thromb Hemost 2011; 37(8): 918-928
DOI: 10.1055/s-0031-1297371
© Thieme Medical Publishers

Doping and Thrombosis in Sports

Giuseppe Lippi1 , Giuseppe Banfi2
  • 1U.O. Diagnostica Ematochimica, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
  • 2I.R.C.C.S Istituto Ortopedico Galeazzi and Università di Milano, Milano, Italy
Further Information

Publication History

Publication Date:
23 December 2011 (online)

    Permissions and Reprints

ABSTRACT

Historically, humans have long sought to enhance their “athletic” performance to increase body weight, aggressiveness, mental concentration and physical strength, contextually reducing fatigue, pain, and improving recovery. Although regular training is the mainstay for achieving these targets, the ancillary use of ergogenic aids has become commonplace in all sports. The demarcation between ergogenic aids and doping substances or practices is continuously challenging and mostly based on perceptions regarding the corruption of the fairness of competition and the potential side effects or adverse events arising from the use of otherwise unnecessary ergogenic substances. A kaleidoscope of side effects has been associated with the use of doping agents, including behavioral, skeletal, endocrinologic, metabolic, hemodynamic, and cardiovascular imbalances. Among the various doping substances, the most striking association with thrombotic complications has been reported for androgenic anabolic steroids (i.e., cardiomyopathy, fatal and nonfatal arrhythmias, myocardial infarction [MI], intracardiac thrombosis, stroke, venous thromboembolism [VTE], limb arterial thrombosis, branch retinal vein occlusion, cerebral venous sinus thrombosis) and blood boosting (i.e., VTE and MI, especially for epoetin and analogs). The potential thrombotic complication arising from misuse of other doping agents such as the administration of cortisol, growth hormone, prolactin, cocaine, and platelet-derived preparations is instead speculative or anecdotal at best. The present article provides an overview on the epidemiological association as well as the underlying biochemical and biological mechanisms linking the practice of doping in sports with the development of thrombosis.

KEYWORDS

Doping - sports - androgenic anabolic steroids - erythropoietin

REFERENCES

  • 1 Simonović D, Simonović A. A New World Is Possible. Belgrade: Autorsko izdanje; 2007
    Google Scholar
  • 2 Lippi G, Franchini M, Guidi G C. Doping in competition or doping in sport?.  Br Med Bull. 2008;  86 95-107
    Google Scholar
  • 3 Lippi G, Guidi G. [Doping and sports].  Minerva Med. 1999;  90 (9) 345-357
    Google Scholar
  • 4 Higgins A J. From ancient Greece to modern Athens: 3000 years of doping in competition horses.  J Vet Pharmacol Ther. 2006;  29 4-8
    Google Scholar
  • 5 Verroken M. Drug use and abuse in sport.  Best Pract Res Clin Endocrinol Metab. 2000;  14 (1) 1-23
    Google Scholar
  • 6 World Anti-Doping Agency (WADA) .Available at: http://www.wada-ama.org/ Last accessed: May 7, 2011
  • 7 Lentillon-Kaestner V, Hagger M S, Hardcastle S. Health and doping in elite-level cycling.  Scand J Med Sci Sports. 2011;  10.1111/j.1600-0838.2010.01281.x [Epub ahead of print]
    Google Scholar
  • 8 Lippi G, Franchini M, Banfi G. Biochemistry and physiology of anabolic androgenic steroids doping.  Mini Rev Med Chem. 2011;  11 (5) 362-373
    Google Scholar
  • 9 Achar S, Rostamian A, Narayan S M. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm.  Am J Cardiol. 2010;  106 (6) 893-901
    Google Scholar
  • 10 Fanton L, Belhani D, Vaillant F et al.. Heart lesions associated with anabolic steroid abuse: comparison of post-mortem findings in athletes and norethandrolone-induced lesions in rabbits.  Exp Toxicol Pathol. 2009;  61 (4) 317-323
    Google Scholar
  • 11 Stergiopoulos K, Brennan J J, Mathews R, Setaro J F, Kort S. Anabolic steroids, acute myocardial infarction and polycythemia: a case report and review of the literature.  Vasc Health Risk Manag. 2008;  4 (6) 1475-1480
    Google Scholar
  • 12 Falkenberg M, Karlsson J, Ortenwall P. Peripheral arterial thrombosis in two young men using anabolic steroids.  Eur J Vasc Endovasc Surg. 1997;  13 (2) 223-226
    Google Scholar
  • 13 Alvarado R G, Liu J Y, Zwolak R M. Danazol and limb-threatening arterial thrombosis: two case reports.  J Vasc Surg. 2001;  34 (6) 1123-1126
    Google Scholar
  • 14 Lippi G, Guidi G, Ruzzenente O, Braga V, Adami S. Effects of nandrolone decanoate (Decadurabolin) on serum Lp(a), lipids and lipoproteins in women with postmenopausal osteoporosis.  Scand J Clin Lab Invest. 1997;  57 (6) 507-511
    Google Scholar
  • 15 Hartgens F, Rietjens G, Keizer H A, Kuipers H, Wolffenbuttel B H. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a).  Br J Sports Med. 2004;  38 (3) 253-259
    Google Scholar
  • 16 Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. A literature review.  Arch Intern Med. 1991;  151 (10) 1925-1933
    Google Scholar
  • 17 Grace F M, Davies B. Raised concentrations of C reactive protein in anabolic steroid using bodybuilders.  Br J Sports Med. 2004;  38 (1) 97-98
    Google Scholar
  • 18 Smith A M, English K M, Malkin C J, Jones R D, Jones T H, Channer K S. Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina.  Eur J Endocrinol. 2005;  152 (2) 285-291
    Google Scholar
  • 19 Anderson R A, Ludlam C A, Wu FCW. Haemostatic effects of supraphysiological levels of testosterone in normal men.  Thromb Haemost. 1995;  74 (2) 693-697
    Google Scholar
  • 20 Nieminen M S, Rämö M P, Viitasalo M et al.. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters.  Eur Heart J. 1996;  17 (10) 1576-1583
    Google Scholar
  • 21 Lowe G D. Anabolic steroids and fibrinolysis.  Wien Med Wochenschr. 1993;  143 (14-15) 383-385
    Google Scholar
  • 22 Ghosh K, Shetty S, Pawar A, Mohanty D. Danazol therapy in factor X deficiency: more questions than answers.  Haemophilia. 2002;  8 (1) 61-62
    Google Scholar
  • 23 Graham M R, Grace F M, Boobier W et al.. Homocysteine induced cardiovascular events: a consequence of long term anabolic-androgenic steroid (AAS) abuse.  Br J Sports Med. 2006;  40 (7) 644-648
    Google Scholar
  • 24 al-Momen A K, Gader A M, Shamena A R, Daif A K, Ajarim D. Significant elevation of protein C and protein S levels in thrombotic disorders by low dose danazol.  Blood Coagul Fibrinolysis. 1991;  2 (4) 495-499
    Google Scholar
  • 25 Ledford M R, Horton A, Wang G, Brito M, Delgado L. Efficacy of danazol in a patient with congenital protein-S deficiency: paradoxical evidence for decreased platelet activation with increased thrombin generation.  Thromb Res. 1997;  87 (5) 473-482
    Google Scholar
  • 26 Bower W A, Humphries J E. Failure of the synthetic androgen, danazol, to increase protein S levels and prevent thrombosis in a patient with severe protein S deficiency.  Haemostasis. 1995;  25 (3) 144-148
    Google Scholar
  • 27 Ajayi A A, Mathur R, Halushka P V. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses.  Circulation. 1995;  91 (11) 2742-2747
    Google Scholar
  • 28 Ferenchick G, Schwartz D, Ball M, Schwartz K. Androgenic-anabolic steroid abuse and platelet aggregation: a pilot study in weight lifters.  Am J Med Sci. 1992;  303 (2) 78-82
    Google Scholar
  • 29 Ajayi A A, Halushka P V. Castration reduces platelet thromboxane A2 receptor density and aggregability.  QJM. 2005;  98 (5) 349-356
    Google Scholar
  • 30 Sullivan P S, Jackson C W, McDonald T P. Castration decreases thrombocytopoiesis and testosterone restores platelet production in castrated BALB/c mice: evidence that testosterone acts on a bipotential hematopoietic precursor cell.  J Lab Clin Med. 1995;  125 (3) 326-333
    Google Scholar
  • 31 Vanberg P, Atar D. Androgenic anabolic steroid abuse and the cardiovascular system.  Handb Exp Pharmacol. 2010;  195 (195) 411-457
    Google Scholar
  • 32 Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible?.  Heart. 2004;  90 (5) 496-501
    Google Scholar
  • 33 Ebenbichler C F, Sturm W, Gänzer H et al.. Flow-mediated, endothelium-dependent vasodilatation is impaired in male body builders taking anabolic-androgenic steroids.  Atherosclerosis. 2001;  158 (2) 483-490
    Google Scholar
  • 34 Lane H A, Grace F, Smith J C et al.. Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids.  Eur J Clin Invest. 2006;  36 (7) 483-488
    Google Scholar
  • 35 Duarte L, Medal L S, Labardini J, Arriaga L. The erythropoietic effects of anabolic steroids.  Proc Soc Exp Biol Med. 1967;  125 (4) 1030-1032
    Google Scholar
  • 36 Alén M. Androgenic steroid effects on liver and red cells.  Br J Sports Med. 1985;  19 (1) 15-20
    Google Scholar
  • 37 Saitoh T, Morimoto K, Kumagai T, Tsuboi I, Aikawa S, Horie T. Comparison of erythropoietic response to androgen in young and old senescence accelerated mice.  Mech Ageing Dev. 1999;  109 (2) 125-139
    Google Scholar
  • 38 Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over.  Semin Thromb Hemost. 2008;  34 (8) 747-761
    Google Scholar
  • 39 Lippi G, Franchini M, Favaloro E J. Unsuspected triggers of venous thromboembolism—trivial or not so trivial?.  Semin Thromb Hemost. 2009;  35 (7) 597-604
    Google Scholar
  • 40 Montagnana M, Favaloro E J, Franchini M, Guidi G C, Lippi G. The role of ethnicity, age and gender in venous thromboembolism.  J Thromb Thrombolysis. 2010;  29 (4) 489-496
    Google Scholar
  • 41 Juhl S, Shorsh K, Videbaek H, Binzer M N. [Concomitant arterial and venous thrombosis in a body builder with severe hyperhomocysteinemia and abuse of anabolic steroids].  Ugeskr Laeger. 2004;  166 (40) 3508-3509
    Google Scholar
  • 42 Liljeqvist S, Helldén A, Bergman U, Söderberg M. Pulmonary embolism associated with the use of anabolic steroids.  Eur J Intern Med. 2008;  19 (3) 214-215
    Google Scholar
  • 43 Alhadad A, Acosta S, Sarabi L, Kölbel T. Pulmonary embolism associated with protein C deficiency and abuse of anabolic-androgen steroids.  Clin Appl Thromb Hemost. 2010;  16 (2) 228-231
    Google Scholar
  • 44 Damasceno E F, Neto A M, Damasceno N A, Horowitz S A, de Moraes Junior H V. Branch retinal vein occlusion and anabolic steroids abuse in young bodybuilders.  Acta Ophthalmol (Copenh). 2009;  87 (5) 580-581
    Google Scholar
  • 45 Sahraian M A, Mottamedi M, Azimi A R, Moghimi B. Androgen-induced cerebral venous sinus thrombosis in a young body builder: case report.  BMC Neurol. 2004;  4 (1) 22
    Google Scholar
  • 46 Jaillard A S, Hommel M, Mallaret M. Venous sinus thrombosis associated with androgens in a healthy young man.  Stroke. 1994;  25 (1) 212-213
    Google Scholar
  • 47 Shiozawa Z, Yamada H, Mabuchi C et al.. Superior sagittal sinus thrombosis associated with androgen therapy for hypoplastic anemia.  Ann Neurol. 1982;  12 (6) 578-580
    Google Scholar
  • 48 Lippi G, Franchini M, Favaloro E J. Thrombotic complications of erythropoiesis-stimulating agents.  Semin Thromb Hemost. 2010;  36 (5) 537-549
    Google Scholar
  • 49 Lippi G, Guidi G. Laboratory screening for erythropoietin abuse in sport: an emerging challenge.  Clin Chem Lab Med. 2000;  38 (1) 13-19
    Google Scholar
  • 50 Lippi G, Franchini M, Salvagno G L, Guidi G C. Biochemistry, physiology, and complications of blood doping: facts and speculation.  Crit Rev Clin Lab Sci. 2006;  43 (4) 349-391
    Google Scholar
  • 51 Lippi G, Banfi G. Blood transfusions in athletes. Old dogmas, new tricks.  Clin Chem Lab Med. 2006;  44 (12) 1395-1402
    Google Scholar
  • 52 Lippi G, Franchini M, Banfi G. Red blood cell-mimicking synthetic biomaterial particles: the new frontier of blood doping?.  Int J Sports Med. 2010;  31 (2) 75-76
    Google Scholar
  • 53 Lippi G, Franchini M. Intermittent hypoxic training: doping or what?.  Eur J Appl Physiol. 2010;  108 (2) 411-412
    Google Scholar
  • 54 Lippi G, Franchini M, Guidi G C. Cobalt chloride administration in athletes: a new perspective in blood doping?.  Br J Sports Med. 2005;  39 (11) 872-873
    Google Scholar
  • 55 Rosenzweig M Q, Bender C M, Lucke J P, Yasko J M, Brufsky A M. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events.  J Pain Symptom Manage. 2004;  27 (2) 185-190
    Google Scholar
  • 56 Bohlius J, Wilson J, Seidenfeld J et al.. Erythropoietin or darbepoetin for patients with cancer.  Cochrane Database Syst Rev. 2006;  3 CD003407
    Google Scholar
  • 57 Bohlius J, Wilson J, Seidenfeld J et al.. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.  J Natl Cancer Inst. 2006;  98 (10) 708-714
    Google Scholar
  • 58 Glaspy J, Crawford J, Vansteenkiste J et al.. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.  Br J Cancer. 2010;  102 (2) 301-315
    Google Scholar
  • 59 Tonia T, Bohlius J. Ten years of meta-analyses on erythropoiesis-stimulating agents in cancer patients.  Cancer Treat Res. 2011;  157 217-238
    Google Scholar
  • 60 Rizzo J D, Brouwers M, Hurley P American Society of Clinical Oncology et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.  J Clin Oncol. 2010;  28 (33) 4996-5010
    Google Scholar
  • 61 Banfi G, Dolci A. Preanalytical phase of sport biochemistry and haematology.  J Sports Med Phys Fitness. 2003;  43 (2) 223-230
    Google Scholar
  • 62 Schmidt W, Biermann B, Winchenbach P, Lison S, Böning D. How valid is the determination of hematocrit values to detect blood manipulations?.  Int J Sports Med. 2000;  21 (2) 133-138
    Google Scholar
  • 63 Braekkan S K, Mathiesen E B, Njølstad I, Wilsgaard T, Hansen J B. Hematocrit and risk of venous thromboembolism in a general population. The Tromso study.  Haematologica. 2010;  95 (2) 270-275
    Google Scholar
  • 64 Reichel C, Benetka E, Geisendorfer T, Scheiblhofer V, Abzieher F. The interference of heparin on IEF-PAGE of erythropoietins.  Drug Test Anal. 2010;  2 (11-12) 568-575
    Google Scholar
  • 65 Iseki K, Nishime K, Uehara H et al.. Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients.  Nephron. 1996;  72 (1) 30-36
    Google Scholar
  • 66 Jeong S K, Cho Y I, Duey M, Rosenson R S. Cardiovascular risks of anemia correction with erythrocyte stimulating agents: should blood viscosity be monitored for risk assessment?.  Cardiovasc Drugs Ther. 2010;  24 (2) 151-160
    Google Scholar
  • 67 Unger E F, Thompson A M, Blank M J, Temple R. Erythropoiesis-stimulating agents—time for a reevaluation.  N Engl J Med. 2010;  362 (3) 189-192
    Google Scholar
  • 68 Mastromarino V, Volpe M, Musumeci M B, Autore C, Conti E. Erythropoietin and the heart: facts and perspectives.  Clin Sci (Lond). 2011;  120 (2) 51-63
    Google Scholar
  • 69 Voors A A, Belonje A M, Zijlstra F HEBE III Investigators et al. A single dose of erythropoietin in ST-elevation myocardial infarction.  Eur Heart J. 2010;  31 (21) 2593-2600
    Google Scholar
  • 70 Ott I, Schulz S, Mehilli J REVIVAL-3 Study Investigators et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial.  Circ Cardiovasc Interv. 2010;  3 (5) 408-413
    Google Scholar
  • 71 Lippi G, Maffulli N. Biological influence of physical exercise on hemostasis.  Semin Thromb Hemost. 2009;  35 (3) 269-276
    Google Scholar
  • 72 Banfi G, Del Fabbro M. Biological variation in tests of hemostasis.  Semin Thromb Hemost. 2008;  34 (7) 635-641
    Google Scholar
  • 73 van Zaane B, Reuwer A Q, Büller H R, Kastelein J J, Gerdes V E, Twickler M T. Hormones and cardiovascular disease: a shift in paradigm with clinical consequences?.  Semin Thromb Hemost. 2009;  35 (5) 478-487
    Google Scholar
  • 74 Targher G, Pichiri I, Zoppini G, Bonora E, Chonchol M. Hemostatic and fibrinolytic abnormalities in endocrine diseases: a narrative review.  Semin Thromb Hemost. 2009;  35 (7) 605-612
    Google Scholar
  • 75 Franchini M, Lippi G, Manzato F, Vescovi P P, Targher G. Hemostatic abnormalities in endocrine and metabolic disorders.  Eur J Endocrinol. 2010;  162 (3) 439-451
    Google Scholar
  • 76 Squizzato A, Van Zaane B, Gerdes V E, Büller H R. The influence of pituitary, adrenal, and parathyroid hormones on hemostasis and thrombosis.  Semin Thromb Hemost. 2011;  37 (1) 41-48
    Google Scholar
  • 77 Lippi G, Plebani M, Cervellin G. Cocaine in acute myocardial infarction.  Adv Clin Chem. 2010;  51 53-70
    Google Scholar
  • 78 Mei-Dan O, Lippi G, Sánchez M, Andia I, Maffulli N. Autologous platelet-rich plasma: a revolution in soft tissue sports injury management?.  Phys Sportsmed. 2010;  38 (4) 127-135
    Google Scholar
  • 79 Kujala U M, Marti P, Kaprio J, Hernelahti M, Tikkanen H, Sarna S. Occurrence of chronic disease in former top-level athletes. Predominance of benefits, risks or selection effects?.  Sports Med. 2003;  33 (8) 553-561
    Google Scholar

Giuseppe LippiM.D. 

Professor, U.O. Diagnostica Ematochimica

Azienda Ospedaliero-Universitaria di Parma, Via Gramsci, 14, 43100 Parma, Italy

Email: giuseppe.lippi@univr.it

Email: ulippi@tin.it

Email: glippi@ao.pr.it